Drug Profile
TOP 1288
Alternative Names: TOP-1288Latest Information Update: 28 Mar 2020
Price :
$50
*
At a glance
- Originator TopiVert
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ulcerative colitis
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for phase-I development in Ulcerative-colitis(In volunteers) in United Kingdom (PO)
- 08 Jan 2018 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in Ulcerative colitis released by TopiVert Pharma (PO)
- 28 Jun 2017 AbbVie completes a phase II trial in Ulcerative colitis in Hungary, Latvia, Lithuania, Poland, United Kingdom, Czech Republic, Bulgaria and Ukraine (Rectal) (NCT02888379)